Wiegelmann W, Solbach H G, Kley H K, Rudorff K H, Herrmann J, Zimmermann H, Krüskemper H L
Dtsch Med Wochenschr. 1975 Feb 21;100(8):331-4. doi: 10.1055/s-0028-1106216.
The synthetic linear tetradekapeptide somatostatin (growth-hormone release inhibitory hormone: GHRIH) inhibits the liberation of growth hormone in normal persons in the insulin hypoglycaemia test without influencing the rise of cortisol and prolactin, while the concentrations of LH, FSH and TSH remain unchanged. In patients with florid acromegaly there occurs during administration of GHRIH a marked fall in the raised STH level without influencing the basal level of the other anterior-pituitary hormones. As a further effect there is suppression of the insulin level. The somatostatin at present available has a very short biological half-life and in its present form is, therefore, without therapeutic importance.
合成的线性十四肽生长抑素(生长激素释放抑制激素:GHRIH)在胰岛素低血糖试验中可抑制正常人生长激素的释放,而不影响皮质醇和催乳素的升高,同时促黄体生成素(LH)、促卵泡生成素(FSH)和促甲状腺激素(TSH)的浓度保持不变。在活动性肢端肥大症患者中,给予GHRIH时,升高的生长激素(STH)水平会显著下降,而不影响其他垂体前叶激素的基础水平。此外,还会抑制胰岛素水平。目前可用的生长抑素生物半衰期非常短,因此以其目前的形式没有治疗意义。